These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cellular and tissue distribution of intravenously administered agalsidase alfa. Murray GJ; Anver MR; Kennedy MA; Quirk JM; Schiffmann R Mol Genet Metab; 2007 Mar; 90(3):307-12. PubMed ID: 17188539 [TBL] [Abstract][Full Text] [Related]
25. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393 [TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510 [TBL] [Abstract][Full Text] [Related]
27. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Lee K; Jin X; Zhang K; Copertino L; Andrews L; Baker-Malcolm J; Geagan L; Qiu H; Seiger K; Barngrover D; McPherson JM; Edmunds T Glycobiology; 2003 Apr; 13(4):305-13. PubMed ID: 12626384 [TBL] [Abstract][Full Text] [Related]
28. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868 [TBL] [Abstract][Full Text] [Related]
29. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease. Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149 [TBL] [Abstract][Full Text] [Related]
30. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Kaneski CR; Moore DF; Ries M; Zirzow GC; Schiffmann R Neurology; 2006 Dec; 67(11):2045-7. PubMed ID: 17159117 [TBL] [Abstract][Full Text] [Related]
31. The kinetics and tissue distribution of protein transduction in mice. Cai SR; Xu G; Becker-Hapak M; Ma M; Dowdy SF; McLeod HL Eur J Pharm Sci; 2006 Mar; 27(4):311-9. PubMed ID: 16376528 [TBL] [Abstract][Full Text] [Related]
32. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Schiffmann R; Rapkiewicz A; Abu-Asab M; Ries M; Askari H; Tsokos M; Quezado M Virchows Arch; 2006 Mar; 448(3):337-43. PubMed ID: 16315019 [TBL] [Abstract][Full Text] [Related]
33. Fabry's disease--an important risk factor for stroke. Schiffmann R; Ries M Lancet; 2005 Nov; 366(9499):1754-6. PubMed ID: 16298202 [No Abstract] [Full Text] [Related]
34. Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain. Lee KO; Luu N; Kaneski CR; Schiffmann R; Brady RO; Murray GJ Biochem Biophys Res Commun; 2005 Nov; 337(2):701-7. PubMed ID: 16223608 [TBL] [Abstract][Full Text] [Related]
35. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287 [TBL] [Abstract][Full Text] [Related]